Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes
Status:
Recruiting
Trial end date:
2024-10-30
Target enrollment:
Participant gender:
Summary
Single center, single-dose, randomized, placebo-controlled, dose-escalating study to
evaluate, safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating doses of
ENT-03S in obese but otherwise healthy subjects and in subjects with obesity and Type 2
diabetes.